Svetlana Lucas
Director/Board Member at ATYR PHARMA, INC.
Net worth: 9 570 $ as of 2024-04-29
Profile
Dr. Svetlana Lucas is an Independent Director at aTyr Pharma, Inc. and a Chief Business Officer at Scribe Therapeutics, Inc. She is on the Board of Directors at aTyr Pharma, Inc. Dr. Lucas was previously employed as a Senior Vice President-Business Development by Tizona Therapeutics, Inc. and a Head-Oncology & Inflammation by Amgen, Inc. She received her undergraduate degree from Moscow State University Lomonosov and a doctorate degree from California Institute of Technology.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
ATYR PHARMA, INC.
0.01% | 2024-05-21 | 6,000 ( 0.01% ) | 9 570 $ | 2024-04-29 |
Svetlana Lucas active positions
| Companies | Position | Start |
|---|---|---|
| ATYR PHARMA, INC. | Director/Board Member | 2019-06-27 |
Scribe Therapeutics, Inc.
 Scribe Therapeutics, Inc. BiotechnologyHealth Technology Scribe Therapeutics, Inc. engages in the development of in vivo therapies. It develops custom engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine. The company was founded by Jennifer A. Doudna, Benjamin L. Oakes, David F. Savage, and Brett T. Staahl and is headquartered in Berkeley, CA. | Corporate Officer/Principal | - |
Former positions of Svetlana Lucas
| Companies | Position | End |
|---|---|---|
Tizona Therapeutics, Inc.
 Tizona Therapeutics, Inc. BiotechnologyHealth Technology Tizona Therapeutics, Inc. is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases. Its products include anti-ccr4 antibody for the treatment of cancer, il-35 antagonists for the treatment of cancer, and il-35 agonists for the treatment of autoimmune diseases. The company was founded by Charles G. Drake, Vijay K. Kuchroo, Drew M. Pardoll, Dario Vignali, Wayne A. Marasco and Jedd D. Wolchok and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 2019-05-31 |
| AMGEN INC. | Corporate Officer/Principal | 2015-06-30 |
Training of Svetlana Lucas
| California Institute of Technology | Doctorate Degree |
| Moscow State University Lomonosov | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| ATYR PHARMA, INC. | Health Technology |
| AMGEN INC. | Health Technology |
| Private companies | 2 |
|---|---|
Tizona Therapeutics, Inc.
Tizona Therapeutics, Inc. BiotechnologyHealth Technology Tizona Therapeutics, Inc. is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases. Its products include anti-ccr4 antibody for the treatment of cancer, il-35 antagonists for the treatment of cancer, and il-35 agonists for the treatment of autoimmune diseases. The company was founded by Charles G. Drake, Vijay K. Kuchroo, Drew M. Pardoll, Dario Vignali, Wayne A. Marasco and Jedd D. Wolchok and is headquartered in South San Francisco, CA. | Health Technology |
Scribe Therapeutics, Inc.
Scribe Therapeutics, Inc. BiotechnologyHealth Technology Scribe Therapeutics, Inc. engages in the development of in vivo therapies. It develops custom engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine. The company was founded by Jennifer A. Doudna, Benjamin L. Oakes, David F. Savage, and Brett T. Staahl and is headquartered in Berkeley, CA. | Health Technology |
- Stock Market
- Insiders
- Svetlana Lucas
